Table 1.
Antiretroviral Agents Suitable for Concomitant Treatment of HIV and Hepatitis C Virus in the Context of Opioid Substitution Therapy
| HCV PI | Antiretroviral Agents, by Class |
|||
|---|---|---|---|---|
| NRTI | NNRTI | PI | II | |
| Boceprevir | Tenofovira
Abacavir Lamivudine Emtricitabine |
Etravirineb | An ongoing study is evaluating drug–drug interactions between boceprevir and HIV PIs | Raltegravir |
| Telaprevir | Tenofovira
Abacavir Lamivudine Emtricitabine |
Etravirine Rilpivirine Efavirenz (telaprevir dose must be increased from 750 mg/tid to 1125 mg/tid) |
aAtazanavir/ritonavir | Raltegravir |
Abbreviations: HIV, human immunodeficiency virus; II, HIV integrase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; tid, 3 times a day.
a Monitoring for toxicity is recommended.
b In healthy volunteers, boceprevir decreased etravirine area under the curve, Cmax, and Cmin, but clinical significance is not clear; when etravirine is coadministered with methadone or buprenorphine, clinical monitoring is recommended and dose adjustments may be necessary.
Sources: De Kanter C, Blonk M, Colbers A, et al. The influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5–8 March 2012. Abstract 772LB.
Hammond KP, Wolfe P, Burton JR Jr, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013; 62:67–73.
US Food and Drug Administration. Intelence (etravirine) Prescribing information. August 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022187s010lbl.pdf Accessed 5 February 2013.
Van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals [published online ahead of print 23 January 2013]. Antivir Ther 2013. PMID: 23344266.